Strategic acquisitions and innovative drugs to drive growth for Pfizer

17 November 2016

In an expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, considers what is next for the pharma giant.

When in 2010 Ian C Read, chief executive of the world’s largest pharmaceutical company, put forward the idea to split Pfizer (NYSE: PFE) into two core businesses, investors and shareholders alike had doubts that the move would create more value and generate attractive opportunities for the company’s innovative and essential health operations.

After almost six years of extensive planning and evaluations, and a costly $600 million exercise, Pfizer announced that it would abandon its plans to split and remain one company – a move which is seen by many as helpful to Pfizer’s retention of operational strength, efficiency and financial flexibility.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK